Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients

Liver International

Volumn 35, Issue s1, 2015, Pages 65-70

  Peter, Joy ^a   Nelson, David R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Direct acting antivirals; Hepatitis C; Treatment

Indexed keywords

ANTIVIRAL AGENTS; BENZIMIDAZOLES; BMS-790052; FLUORENES; IMIDAZOLES; LEDIPASVIR; SOFOSBUVIR; URIDINE MONOPHOSPHATE;

ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG THERAPY, COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; METHODS; TRENDS;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INDIVIDUALIZED MEDICINE; URIDINE MONOPHOSPHATE;

EID: 84919628495     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12718     Document Type: Review

References (27)

1. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-14.
2. Afdhal N, Reddy KR, Nelson DR, ION-2 Investigators, et al. Ledipasvir and sofosbuvir for previously treated genotype 1 infection. N Engl J Med 2014; 379: 1483-93.
3. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
4. Sulkowski MS1, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
5. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
6. Zeuzem S, Dusheiko GM, Salupere R, VALENCE Investigators, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
7. Nelson D, Cooper JN, Lalezari JP, et al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in patients infected with HCV genotype (GT)3: ALLY-3 phase 3 study (Abstract). Hepatology 2014; 60(Suppl.): 6.
8. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; pii: S0140-6736(14)61036-9.
9. Andreone P1, Colombo MG2, Enejosa JV3, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-65 e1.
10. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
11. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
12. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2014; 12: 728-37.
13. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
14. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30ra32.
15. EASL Recommendations on Treatment of Hepatitis C. 2014. Available at http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014. Accessed: 5 October 2014.
16. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org. Accessed: 5 October 2014.
17. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56: 3359-68.
18. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
19. Lok AS1, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
20. Lok AS, Gardiner DF, Hézode C, et al. Randomized trial of daclatasvir and asunaprevir with or without peg-IFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490-9.
21. Lee C. Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther 2013; 7: 1223-33.
22. Cheng G, Peng B, Corsa A, et al. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885. J Hepatol 2012; 56: S464.
23. ®. Full Prescribing Information, Foster City, CA: Gilead, 2014.
24. Bourliere M, Bronowicki J, Ledinghen V, et al. Ledipasvir/Sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy (Abstract). Hepatology 2014; 60(Suppl.): 13.
25. Dvory-Sobol H, Doehle B, Svarovskaia E, et al. The prevalence of HCVNS5A, nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir/sofosbuvir +/- ribavirin in the phase 3 ION studies. International Workshop on Antiviral Drug Resistance, Berlin, Germany, June 2014.
26. Menon RM, Klein CE, Lawal AA, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. Presented at the annual meeting of HepDART, Kohala Coast, HI, 6-10 December 2009.
27. Hezode C, Marcellin P, Pol S, et al. Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450/r+ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. Presented at the annual meeting of EASL, London, UK, 9-13 April.